Adult Vaccines are an essential component of preventive healthcare, offering protection against a range of infectious diseases that can pose serious risks to adults' health and well-being. While often overshadowed by childhood vaccination programs, adult immunization is equally crucial for maintaining individual health and preventing the spread of contagious illnesses within communities. Influenza, commonly known as the flu, is a prime example of a vaccine-preventable disease that affects millions of adults worldwide each year. Annual flu vaccination is recommended for all adults, particularly those at higher risk of complications, such as older adults, pregnant women, and individuals with chronic health conditions.
Another important adult vaccine is the tetanus, diphtheria, and pertussis (Tdap) vaccine. Tetanus, a bacterial infection that affects the nervous system, can be transmitted through wounds or cuts and can lead to severe muscle spasms and respiratory failure. The Tdap vaccine provides protection against tetanus, diphtheria, and pertussis (whooping cough) and is recommended for adults who have not received a Tdap vaccine previously. Human papillomavirus (HPV) vaccine is another critical immunization for adults, particularly for those who may not have been vaccinated during adolescence. Vaccination against HPV can help prevent these cancers and is recommended for adults up to age 45.
Despite the clear benefits of adult vaccination, coverage rates remain suboptimal. Barriers to vaccination include lack of awareness, limited access to healthcare services, and vaccine hesitancy. Public health efforts are needed to increase awareness of the importance of adult immunization, improve access to vaccines, and address misconceptions about vaccine safety and efficacy.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States